Amgen Inc. $AMGN Shares Bought by Cerity Partners LLC

Cerity Partners LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 423,019 shares of the medical research company’s stock after purchasing an additional 16,972 shares during the quarter. Cerity Partners LLC owned approximately 0.08% of Amgen worth $118,120,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its holdings in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the period. Chicago Partners Investment Group LLC raised its stake in Amgen by 21.1% during the first quarter. Chicago Partners Investment Group LLC now owns 5,839 shares of the medical research company’s stock worth $1,819,000 after purchasing an additional 1,019 shares during the period. Founders Financial Alliance LLC boosted its holdings in shares of Amgen by 2.7% in the 1st quarter. Founders Financial Alliance LLC now owns 1,577 shares of the medical research company’s stock valued at $491,000 after purchasing an additional 42 shares during the last quarter. Townsquare Capital LLC boosted its holdings in shares of Amgen by 27.3% in the 1st quarter. Townsquare Capital LLC now owns 40,954 shares of the medical research company’s stock valued at $12,759,000 after purchasing an additional 8,789 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Amgen by 13.9% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 61,712 shares of the medical research company’s stock valued at $19,226,000 after buying an additional 7,536 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AMGN. Piper Sandler lifted their target price on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. The Goldman Sachs Group restated a “buy” rating on shares of Amgen in a report on Tuesday, November 25th. HSBC boosted their target price on Amgen from $343.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday. Finally, DZ Bank lifted their price target on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $335.65.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $329.89 on Friday. The business’s 50-day simple moving average is $313.41 and its 200 day simple moving average is $297.25. The company has a market cap of $177.64 billion, a P/E ratio of 25.49, a PEG ratio of 2.98 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. Amgen Inc. has a one year low of $253.30 and a one year high of $346.38.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter last year, the company earned $5.58 earnings per share. Amgen’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be issued a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a yield of 2.9%. Amgen’s payout ratio is currently 73.57%.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 890 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 in the last ninety days. Insiders own 0.76% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.